Large Study Seeks Early-Life Risk Factors for NHL

A diagnosis of non-Hodgkin's lymphoma in children, adolescents and young adults is rather rare, and tends to constitute a very small percentage of the annual number of diagnoses. However, some researchers believe that while NHL diagnoses are stabilizing among adults, they are growing in incidence among younger people.

In order to try and determine what factors may be at work in this potential rise in incidence, researchers from the Department of Medicine at Stanford University conducted a national cohort study of in excess of 3.5 million people born in Sweden between the years 1973 and 2008, who were subsequently followed for NHL incidence.

Their findings have been published in the most recent issue of the Journal of the National Cancer Institute.

Factors they were able to determine that influenced non-Hodgkin's lymphoma development among young people included the following:

  • -- Family genetics
  • -- Family history (NHL in a sibling or parent)
  • -- High fetal growth
  • -- Older maternal age
  • -- Low birth order
  • -- Male gender (in kids under the age of 15 only)

According to the study authors:

"These findings suggest several heterogeneous mechanisms including possible growth factor pathways in utero, immunologic effects of delayed infectious exposures, as well as other unmeasured environmental and genetic factors. Further elucidation of these risk factors may facilitate the identification of high-risk individuals at young ages and potentially enable earlier detection and treatment."

Source: Science Codex

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap